A tabulated summary of the FDG PET literature

Journal of Nuclear Medicine

Volumn 42, Issue 5 SUPPL., 2001, Pages

  Gambhir, S S ^a   Czernin, J ^a   Schwimmer, J ^a   Silverman, D H S ^a   Coleman, R E ^a   Phelps, M E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cardiology; FDG PET; Health Care Financing Administration; Literature review; Neurology; Oncology

Indexed keywords

FLUORODEOXYGLUCOSE;

ADULT; BREAST CANCER; CANCER STAGING; DATA ANALYSIS; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DIGESTIVE SYSTEM CANCER; FEMALE; HEAD AND NECK CANCER; HEART INFARCTION; HUMAN; IMAGE ANALYSIS; LUNG CANCER; LYMPHOMA; MALE; MEDICAL LITERATURE; MEDICAL RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUBLICATION; REVIEW; SCHOOL CHILD; SEIZURE; SENSITIVITY AND SPECIFICITY; THYROID CANCER; UROGENITAL TRACT CANCER;

BIBLIOMETRICS; BRAIN; CORONARY DISEASE; DEMENTIA; FLUORODEOXYGLUCOSE F18; HUMANS; MYOCARDIUM; NEOPLASMS; RADIOPHARMACEUTICALS; SEIZURES; TISSUE SURVIVAL; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0035021707     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (474)

1. Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors
2. Preoperative evaluation of patients with suspected liver metastases with positron emission tomography with F-18 FDG
3. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: Correlation with histopathologic and CT findings
4. Single-voxel proton MR spectroscopy and positron emission tomography for lateralization of refractory temporal lobe epilepsy
5. The value of positron emission tomography scanning in the detection of subclinical metastatic melanoma
6. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer
7. Evaluation of breast masses and axillary lymph nodes with [F-18] 2 deoxy-2-fluoro-D-glucose PET
8. Axillary lymph node metastases: Screening with [F-18]2 deoxy-2-D-glucose (FDG) PET
9. Positron emission tomography of thyroid masses
10. Cerebral metabolism of the remote area after epilepsy surgery
11. Relative diagnostic efficacy of F-18 FDG PET and bone scintigraphy for detection of osseous metastases in primary or secondary lung cancer
12. Positron emission tomography in the clinical staging of patients with stage I and II testicular germ cell tumors
13. Improvement of non-small-cell lung cancer staging by means of positron emission tomography
14. FDG PET of recurrent or metastatic 1311-negative papillary thyroid carcinoma
15. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans
16. Whole body FDG-PET before laser-induced thermo-therapy (LITT) in patients with hepatic metastases of colorectal cancer
17. Recurrence of head and neck cancer after surgery or irradiation: Prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses
18. Positron emission tomography in the detection of residual laryngeal carcinoma
19. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose
20. Monitoring primary chemotherapy in advanced breast cancer using FDG-PET
21. Positron emission tomography: Introduction of a new imaging technique for urological tumors and initial clinical results
22. Positron emission tomography (PET) for diagnosis of renal cell carcinoma (RCC)
23. Lymph node staging for urinary bladder carcinoma with positron emission tomography (PET)
24. Contribution of nuclear medicine to the diagnosis of recurrent brain tumors and cerebral radionecrosis
25. Diagnostic efficiency in the detection of brain tumor recurrence at follow-up by 1231 alpha-methyltyrosine-SPECT and 18FDG-PET
26. Oncologic information provided by immunoscintigraphy with 99mTc Fab fragments compared with (18F)FDG PET in colorectal cancer
27. Predictive value of low-dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of left ventricular function after successful revascularization
28. Positron emission tomography with 18-fluorodeoxyglucose in the staging and follow-up of lymphoma in the chest
29. Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography FDG-PET for accurate staging of Hodgkin's disease
30. Results of positron emission tomography with fluorine-18-labeled fluorodeoxyglucose in differential diagnosis and staging of pancreatic carcinoma
31. Somatostatin receptor scintigraphy in malignant lymphoma: First results and comparison with glucose metabolism measured by positron emission tomography
32. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer
33. Pancreatic cancer detected by positron emission tomography with 18F-labelled deoxyglucose: Method and first results
34. Clinical value of "ictal" FDG-positron emission tomography and the routine use of simultaneous scalp EEG studies in patients with intractable partial epilepsies
35. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer
36. Staging of non-small cell lung cancer (NSCLC): Is PET really clinically important or just a research tool?
37. Clinical value of whole-body positron emission tomography with [18F] fluorodeoxyglucose in recurrent colorectal cancer
38. Evaluation of the internal mammary (IM) lymph node (LN) chain by PET in locally advanced breast cancer (LABC)
39. The role of FDG-PET in the preoperative assessment of N-staging in head and neck cancer
40. Possible role of FDG-PET in the early prediction of therapy outcome in liver metastases of colorectal cancer
41. Value of 18-fluorodeoxyglucose positron emission tomography in the staging of recurrent breast carcinoma
42. Pilot study of positron emission tomography in patients with advanced head and neck cancer receiving radiotherapy and chemotherapy
43. Assessment of internal mammary lymph nodes by fluorodeoxyglucose positron emission tomography (FDG-PET) in medial hemisphere breast cancer
44. Neuroimaging in the evaluation of suspected brain tumor recurrence in the pediatric population, the critical role of fluorodeoxyglucose (18-FDG) positron emission tomography (PET) studies
45. Diagnostic value of 18F-FDG PET in detecting carcinoma of the oral mucosa in comparison with MRI, CT, and ultrasound (US)
46. Chemotherapy response monitoring with FDG positron emission tomography of patients with small cell lung cancer
47. Effect of attenuation correction on lesion detectability in FDG PET of breast cancer
48. Positron emission tomography and ultrasonography. A comparative retrospective study assessing the diagnostic validity in lymph node metastases of malignant melanoma
49. Improvement in staging of esophageal cancer with addition of positron emission tomography
50. Determination of malignancy of thyroid nodules with positron emission tomography
51. Bilateral temporal hypometabolism in epilepsy
52. Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences. Early observations
53. Post-treatment 18F-FDG-PET as predictor for disease-free survival in Hodgkin's lymphoma
54. FDG PET detection of unknown primary tumors
55. Correlation of 18F FDG-PET and histological findings in patients with malignant melanoma
56. FDG-PET in the assessment of axillary metastases in breast cancer. Clinical application and economic implications
57. Dual-head FDG-PET for the detection of recurrent laryngeal cancer compared with histopathological biopsy results and minimally 1-year clinical follow-up
58. Staging of metastatic melanoma by whole-body positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-D-glucose
59. 18F FDG-PET in clinical assessment of primary uterine cervical carcinoma: Detection and correlation with tumor oxygen partial pressure
60. Detection of lymph node metastases of squamous cell cancer of the head and neck with FDG-PET and MRI
61. Detection of unknown primary head and neck tumors by positron emission tomography
62. The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer
63. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer
64. Evaluation of the solitary pulmonary nodule by positron emission tomography imaging
65. Staging of the mediastinum: Value of positron emission tomography imaging in non-small cell lung cancer
66. FDG-PET for staging recurrent esophageal cancer (EC)
67. Evaluation of prostate cancer using high-resolution FDG PET imaging
68. Detection of lymphoma in bone marrow by whole-body positron emission tomography
69. Experience with positron emission tomography (PET) scans in patients with ovarian cancer
70. Positron emission tomography with fluoro-deoxyglucose to evaluate tumor response and control after radiation therapy
71. Diagnostic accuracy of F-18 FDG-PET in the assessment of post-therapeutic recurrence of head and neck cancer
72. FDG PET role in differential diagnosis of pancreatic and peri-pancreatic masses
73. Mediastinal staging of non-small-cell lung cancer with positron emission tomography
74. PET and lymphoscintigraphic evaluation of malignant melanomas: The Hadassah Hospital experience
75. Improved detection of individual nodal involvement in squamous cell carcinoma of the esophagus by FDG PET
76. Surgical treatment of intractable neonatal-onset seizures: The role of positron emission tomography
77. Value of FDG PET in papillary thyroid carcinoma with negative 1311 whole-body scan
78. Correlation of fine needle aspiration biopsy and fluoride-18 fluorodeoxyglucose positron emission tomography in the assessment of locally recurrent and metastatic head and neck neoplasia
79. Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography
80. Discrepant performance of FDG-PET and magnetic resonance imaging (MRI) and spectroscopy (MRS) for the detection of brain tumor recurrence between adults and children
81. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer
82. Positron emission tomography with 18F-FDG to detect residual disease after therapy for malignant lymphoma
83. Does positron emission tomography using 18-fluoro-2-deoxyglucose improve clinical staging of testicular cancer? Results of a study in 50 patients
84. Skeletal metastases in lung cancer: Accuracy of 18FDG-PET in correlation with bone scintigraphy
85. Evaluation of adrenal masses in lung cancer using 18FDG PET
86. The contribution of positron emission tomography (PET) with 18F-fluorodeoxyglucose (FDG) in the preoperative detection of axillary metastases of breast cancer: The experience of the National Cancer Institute of Milan
87. Prospective evaluation of fluorine-18 FDG PET in presurgical staging of the axilla in breast cancer
88. Positron emission tomography and breast masses: Comparison with clinical, mammographic, and pathological findings
89. Landau-Kleffner syndrome: Metabolic abnormalities in temporal lobe are a common feature
90. Positron emission tomography in the detection and management of metastatic melanoma
91. Positron emission tomographic study of late-onset cryptogenic symptomatic seizures
92. FDG PET is highly accurate in the diagnosis of chronic osteomyelitis in the central skeleton
93. Germ cell tumor: Staging with FDG-PET. Pilot phase of the German multicenter trial
94. Wholebody positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma
95. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy
96. Postsurgical outcome of patients with uncontrolled complex partial seizures and temporal lobe hypometabolism on 18FDG-positron emission tomography
97. Evaluation of benign vs malignant hepatic lesions with positron emission tomography
98. 18F-fluorodeoxyglucose imaging with positron emission tomography in the follow-up of patients with lymphoma
99. 18F-fluorodeoxyglucose imaging with positron emission tomography for initial staging of Hodgkin's disease and lymphoma
100. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma
101. Staging recurrent metastatic colorectal carcinoma with PET
102. Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma
103. Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management
104. PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis
105. Results of pretherapeutic lymph node diagnosis in head and neck tumors. Clinical value of 18-FDG positron emission tomography (PET)
106. Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer
107. Follow-up of differentiated thyroid cancer: What is the value of FDG and sestamibi in the diagnostic algorithm?
108. Positron emission tomography (PET) with 18F-deoxyglucose (FDG) in tumors of the skeleton system
109. PET with FDG in soft tissue sarcomas
110. Evaluation of tumour metabolism and multidrug resistance in patients with treated malignant lymphomas
111. Therapeutic relevance of FDG-PET in untreated Hodgkin's disease and high-grade non-Hodgkin lymphoma
112. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET)
113. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography
114. Use of positron emission tomography for presurgical localization of eloquent brain areas in children with seizures
115. Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma
116. Presurgical evaluation for partial epilepsy: Relative contributions of chronic depth-electrode recordings versus FDG-PET and scalp-sphenoidal ictal EEG
117. Positron emission tomography using 18F-fluorodeoxyglucose in patients with stereotactically irradiated brain metastases
118. Assessment of mediastinal lymph node metastasis in advanced breast cancer: Comparison of FDG PET with CT
119. Detection of recurrent head and neck squamous cell carcinomas after radiation therapy with 2-18F-fluoro-2-deoxy-D-glucose positron emission tomography
120. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer
121. Preoperative assessment of asymptomatic adnexal tumors by positron emission tomography and F-18 fluorodeoxyglucose
122. Focal abnormalities detected by 18FDG PET in epileptic encephalopathies
123. Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: Correlation with tumor response to fluorouracil
124. (F-18)-FDG-PET in primary staging of malignant lymphoma: First results of a multicenter study
125. Clinical utility of positron emission tomography with 18F-fluoro-deoxy glucose in detecting residual/recurrent squamous cell carcinoma of the head and neck
126. Additional value of positron emission tomography (PET) with fluorodeoxyglucose (FDG) in recurrent colorectal cancer: A study in 103 patients
127. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer
128. Staging of esophageal cancer with 18F-fluorodeoxyglucose positron emission tomography
129. Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer
130. EEG, PET, SPET and MRI in intractable childhood epilepsies: Possible surgical correlations
131. Early monitoring of treatment response by (18F)FDG-PET in preoperatively irradiated advanced oral cancer
132. 18-FDG positron emission tomography of the pancreas: Diagnostic benefit in the follow-up of pancreatic carcinoma
133. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomoraphy
134. Detection of liver metastases from pancreatic cancer using FDG PET
135. The usefulness of breast cancer screening using 18F FDG PET
136. Evaluation of esophageal cancers using fluorine-18-fluorodeoxyglucose PET
137. 18F-FDG and 11C-methionine PET for evaluation of suspected recurrent colorectal cancer
138. High negative predictive value of FDG-PET for assessment of progressive disease in patients with soft tissue sarcoma
139. Myocardial blood flow, glucose uptake, and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction: Implications for the pathophysiology of chronic myocardial hibernation
140. Preoperative and intraoperative uptake of 18FDG-PET in axillary metastases of breast cancer. A pathological correlation
141. Evaluation of malignancy-related pleural disease with FDG-positron emission tomography (PET)
142. Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: Potential role in oncologic imaging
143. Classification of asymptomatic adnexal masses by ultrasound, magnetic resonance imaging, and positron emission tomography
144. Occult primary tumors of the head and neck: Lack of benefit from positron emission tomography imaging with 2-[F-18]fluoro-2-deoxy-D-glucose
145. Distinguishing tumor recurrence from irradiation sequelae with positron emission tomography in patients treated for larynx cancer
146. Positron emission tomography of patients with head and neck carcinoma before and after high dose irradiation
147. FDG-PET evaluation of primary carcinoma of the cervix
148. Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy- D-glucose in the imaging of malignant melanoma
149. Comparison of carbon-11-acetate with fluorine-18-fluorodeoxyglucose for delineating viable myocardium by positron emission tomography
150. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: Results of a multicentre study
151. Comparison of 18FDG-PET with 1311 and 99mTc-sestamibi scintigraphy in differentiated thyroid cancer
152. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer
153. Lymph node staging in non-small cell lung cancer: Evaluation by (18F)FDG positron emission tomography (PET)
154. Long-term outcome of patients with indeterminate lung nodules following management based on PET-FDG results
155. Incidence and characteristics of falsely positive and negative lymph node on PET and CT in lung cancer staging
156. Relative utility of PET-FDG and CT scanning in preoperative TNM staging of lung cancer patients
157. Improved pre-operative staging of primary lung cancer by PET-FDG imaging
158. Comparative efficacy of FDG-PET in evaluation of small (less than 3 cm) and large (greater than 3 cm) pulmonary (PUL) and lymph node (LN) lesions
159. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET
160. FDG-PET in the staging work-up of patients with suspected intracranial metastatic tumors
161. Is there any incremental value of routine lymph node sampling using mediastinoscopy and/or thoracotomy or open biopsy for management of lung cancer patients following whole body PET?
162. The role of positron-emission tomography (PET) in the assessment of pathologic response to neoadjuvant chemotherapy with doxorubicin and docetaxel in patients with locally advanced breast cancer
163. Feasibility of detecting unknown primary tumors with gamma camera coincidence PET
164. Fluorodeoxyglucose imaging of advanced head and neck cancer after chemotherapy
165. Value of positron emission tomography with 18-fluorodeoxyglucose (FDG-PET) in early detection of residual tumor in oro-pharyngeal-laryngeal carcinoma
166. Characterization of pulmonary nodules and mediastinal staging of bronchogenic carcinoma with F-18 fluorodeoxyglucose positron emission tomography
167. The value of FDG-PET in recurrent testicular carcinoma
168. Staging of testicular carcinoma with FDG-PET
169. Fluorodeoxyglucose PET in the evaluation of amputations for soft tissue sarcoma
170. Uses and limitations of FDG positron emission tomography in patients with head and neck cancer
171. PET imaging of prostate cancer using carbon-11choline
172. Therapy control of metastatic testicular carcinoma with F18-DOG PET
173. The role of positron emission tomography in selecting patients with metastatic cancer for adrenalectomy
174. Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen positron emission tomography and biopsy correlation
175. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: Preliminary experience
176. Staging of pelvic lymph nodes in neoplasms of the bladder and prostate by positron emission tomography with 2-(18F)-2-deoxy-D-glucose
177. MR and positron emission tomography in the diagnosis of surgically correctable temporal lobe epilepsy
178. Intractable temporal lobe epilepsy: Comparison of positron emission tomography with qualitative and quantitative MR
179. Functional breast imaging: Comparison of 18F-fluorodeoxyglucose (FDG) PET and pharmacokinetic MR mapping (DMRI)
180. Pretreatment studies of 18F-fluorode-oxyglucose (FDG), 1231-[alpha]-methlytyrosine (IMT) and 99mTc-sestamibi uptake in hypopharynx-larynx-carcinomas
181. Comparability of FDG PET studies in probable Alzheimer's disease
182. The utility of flourine- 18 fluorodeoxyglucose (FDG) positron emission tomography (PET) for restaging of non-small cell lung cancer (NSCLC): Analysis of management change and survival in 63 consecutive patients
183. Comparison of fluorine-18-FDG PET and thallium-201 SPECT in evaluation of lung cancer
184. Comparison of 18F FDG PET and 20[T] SPECT in evaluation of pulmonary nodules
185. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET
186. Significance of PET-FDG in comparison with 1311 WBS and serum Tg in detection of recurrent and metastatic papillary thyroid carcinoma
187. FDG-PET imaging in pathologically verified dementia
188. FDG-PET in differentiating lymphoma from nonmalignant central nervous system lesions in patients with AIDS
189. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (FI8-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type
190. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma
191. Prognostic value of whole body FDG PET in breast cancer patients undergoing chemotherapy
192. Evaluation of renal cell carcinoma with whole body FDG
193. Cancer detection with whole-body PET using 2-[18F] fluoro-2-deoxy-D-glucose
194. Quantitative and whole-body FDG PET in the evaluation of suramin therapy in patients with metastatic prostate
195. Effectiveness of positron emission tomography for the detection of melanoma metastases
196. Temporal lobe pathology in epilepsy: Proton magnetic resonance spectroscopy and positron emission tomography study
197. In vivo metabolism of childhood posterior fossa tumors and primitive neuroectodermal tumors before and after treatment
198. FDG-PET as a prognostic indicator in radiochemotherapy of glioblastoma
199. Positron emission tomography plus serum TA90 immune complex assay for detection of occult metastatic melanoma
200. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using (2-[18F]FDG)
201. Differentiating benign from malignant lung lesions using "quantitative" parameters of FDG PET images
202. Characterization of chest masses by FDG positron emission tomography
203. Can the standardized uptake value characterize primary brain tumors on FDG-PET?
204. Imaging of malignant lymphomas with 18F-FDG coincidence detection PET (CoDe-PET)
205. Evaluation of positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose for the differentiation of chronic pancreatitis and pancreatic cancer
206. Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences
207. Mediastinal lymph node staging in non-small cell lung cancer using PET with C-11 choline and F-18 FDG
208. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: Comparison with CT and US
209. Detecting recurrent or residual lung cancer with FDG-PET
210. Myocardial viability assessment using 18F FDG gated PET
211. 67Ga scintigraphy and 18F FDG coincidence imaging in the evaluation of lymphoma
212. Yield of FDG-PET scans for identifying active malignancy in patients with elevated tumour markers
213. Yield of FDG-PET scanning as a routine follow-up exam in patients with malignancy
214. Clinical impact of FDG PET on the management of patients with pancreatic carcinoma: Comparison with CT and CA 19-9 serology
215. The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma
216. Evaluation of suspected recurrent papillary thyroid carcinoma with [18F]fluorodeoxyglucose positron emission tomography
217. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: A method for early therapy evaluation?
218. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors
219. Whole body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
220. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma
221. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma
222. Diagnosis of recurrent brain tumor: Value of 201T1 SPECT vs 18F-fluorodeoxyglucose PET
223. The clinical impact of PET scanning in patients with lung cancer: A prospective
224. Whole-body positron emission tomography with 2-(18F)-fluoro-2-deoxy-D-glucose can detect recurrent ovarian carcinoma
225. Preliminary results of whole body FDG-PET in biliary carcinoma
226. Local recurrence of rectal cancer: Evaluation of F- 18 fluorodeoxyglucose PET imaging
227. Follow-up of ovarian cancer using (18F)-FDG scan with a dual-head coincidence gamma camera (CDET)
228. FDG PET evaluation of head and neck cancer: Value of imaging the thorax
229. Whole-body [18F]FDG PET in the management of metastatic brain tumours
230. FDG-PET in patients with cervical cancer of uterus: Experience in patients with clinically no evidence of disease
231. How useful is 18F-FDG coincidence detection positron emission tomography in the staging of lung cancer?
232. Cerebral gangliogliomas: Preoperative grading using FDG-PET and 201T1-SPECT
233. Value of 18F-FDG PET in detection and staging of perihilar cholangiocarcinoma
234. Impact of 18F-FDG-PET in patients with cancer of unknown primary
235. Evaluation of pulmonary lesions with FDG-PET. Comparison of findings in patients with and without a history of prior malignancy
236. Myocardial viability: Fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization
237. Positron emission tomography for staging of gastroesophageal malignancy
238. Detection of unknown occult primary tumors using positron emission tomography
239. Whole-body PET with FDG: Detection of unknown primary tumors
240. Detection of local recurrence of soft-tissue sarcoma with positron emission tomography using [18F]fluorodeoxyglucose
241. Evaluation of FDG-PET in the detection of bone marrow involvement in lymphoma
242. Comparison of FDG-PET and 67Ga SPECT in the staging of lymphoma
243. Preliminary FDG-PET study in patients with bladder cancer
244. Surgical outcome in patients with epilepsy with occult vascular malformations treated with lesionectomy
245. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma
246. Whole-body positron emission tomography (PET) with 18F-FDG in patients with cancer of unknown primary
247. (18F)2-fluorodeoxyglucose PET. Prospects for secondary prevention of mouth cavity carcinoma
248. Limited value of (18F)FDG-PET in localizing of recurrent/metastatic medullary thyroid carcinoma (MTC)
249. Selective use of PET scan in the preoperative staging of NSCLC
250. The role of whole-body positron emission tomography with [18F] fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver
251. Carcinoma of unknown primary (CUP): Value of whole-body F-18-FDG-PET for detection of the primary tumor
252. Value of wholebody 18F-FDG-PET in metastatic renal cell carcinoma: Correlation with tumor aggressiveness?
253. Whole-body 18F-FDG-PET in patients with suspected recurrence of colorectal cancer: A comparison with CT and MRI
254. Cervical lymph node staging in patients with head and neck cancer: A comparison between 18F-FDG-PET and ultrasound
255. The impact of whole body FDG PET on the management of patients with malignant melanoma
256. Experience in qualitative and quantitative FDG PET in follow-up of patients with suspected recurrence from head and neck cancer
257. Head and neck cancer: Detection of recurrence with PET and 2-[F-18]fluoro-2-deoxy-D-glucose
258. 18F-FDG whole body positron emission tomography (PET) in patients with unknown primary tumours (UPT)
259. Comparison of PET measurements of cerebral blood flow and glucose metabolism for the localization of human epileptic foci
260. FDG PET in childhood soft tissue sarcoma
261. Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer
262. Effectiveness of FDG PET in the detection of recurrent squamous cell carcinoma of the head and neck
263. 18F fluorodeoxyglucose imaging with coincidence dual-head gamma camera (hybrid FDG-PET) for staging of lymphoma: Comparison with 67Ga scintigraphy
264. F-18 FDG imaging with coincidence dual-head gamma camera (co-PET) in staging of lymphoma: Comparison with CT and gallium scans
265. Comparison of fluorine-18fluorodeoxyglucose and carbon-11-methionine in head and neck cancer
266. Limited usefulness of (11C)acetate whole body PET in patients with thyroid cancer
267. A six-hour study of soft tissue masses using FDG PET
268. A PET study of 18FDG uptake in soft tissue masses
269. The role of PET-18FDG in detecting distant recurrence of breast cancer
270. Can dual-headed 18F-FDG SPET imaging reliably supersede PET in clinical oncology? A comparative study in lung and gastrointestinal tract cancer
271. Surveillance for recurrent head and neck cancer using positron emission tomography
272. Evaluation of chemotherapeutic response in patients with advanced head and neck cancer using [F-18] fluorodeoxyglucose positron emission tomography
273. Prospective investigation of positron emission tomography in lung nodules
274. Primary and recurrent early stage laryngeal cancer: Preliminary results of 2-[fluorine 18] fluoro-2-deoxy-D-glucose PET imaging
275. Evaluation of diagnostic testing discrepancies in the management of lung cancer: A review incorporating (F-18)FDG-PET imaging
276. Prospective evaluation of soft tissue masses and sarcomas using fluorodeoxyglucose positron emission tomography
277. Evaluation of fluorodeoxyglucose positron emission tomography in the management of soft-tissue sarcomas
278. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxybutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease
279. Double-blind stereo-EEG and FDG PET study in severe partial epilepsies: Are the electric and metabolic findings related?
280. Evaluation of distant metastases in esophageal cancer: 100 consecutive positron emission tomography scans
281. Role of positron emission tomography in staging esophageal cancer
282. Prospective evaluation of 2-[18F]-2-deoxy-D-glucose positron emission tomography in staging of regional lymph nodes in patients with cutaneous malignant melanoma
283. Assessment of myocardial viability in chronic coronary artery disease using technetium-99m sestamibi SPECT: Correlation with histologic and positron emission tomographic studies and functional follow up
284. FDG/PET and spiral CT image fusion for mediastinal lymph node assessment of non-small cell lung cancer patients
285. Are 18-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
286. The role of FDG-PET in diagnosing suspected tumor recurrence based on increased levels of plasma markers
287. The use of positron emission tomography scanning in occult and recurrent head and neck cancer
288. Comparative study of interictal PET and ictal SPECT in complex partial seizures
289. Staging non-small cell lung cancer with whole-body PET
290. Performance of dedicated, nonattenuation corrected FDG-PET in diagnosis and staging of pancreatic cancer (PCa)
291. Diagnostic performance of whole-body FDG-PET and CT imaging in malignant lymphomas
292. Dual time point 18FDG-PET imaging for the differentiation between benign and malignant pulmonary nodules
293. Changes in fluorodeoxyglucose (FDG) uptake measured by positron emission tomography (PET) in prostate cancer (CaP) patients following androgen withdrawal
294. Whole-body FDG positron emission tomographic imaging for staging esophageal cancer. Comparison with computed tomography
295. Retrospective analysis of standardized uptake values of lung masses with 18F FDG PET
296. Impact of FDG-PET on management of patients with colorectal cancer
297. Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia
298. HMPAO SPET and FDG PET in Alzheimer's disease and vascular dementia: Comparison of perfusion and metabolic pattern
299. Regional cerebral glucose metabolism and postmortem pathology in Alzheimer's disease
300. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas
301. Comparison of FDG scan on a dual-head coincidence gamma camera (CDET) and conventional imaging for the diagnosis of recurrence of colorectal cancer
302. Lymphoma: Role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging
303. Extranodal malignant lymphoma: Detection with FDG PET versus CT
304. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma
305. Accuracy of whole body fluorine- I 8-FDG PET for the detection of recurrent or metastatic breast carcinoma
306. Diagnostic accuracy and predictive value of the tumor-associated antigen S100 in malignant melanomas: Validation by whole body FDG-PET and conventional diagnostics
307. The role of FDG-PET and 201T1 imaging as a preoperative diagnostic tool in recurrent Hürthle cell carcinoma of the thyroid
308. Study on surgical treatment of intractable childhood epilepsy
309. Evaluation of fluorodeoxy-glucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: A clinical and molecular study
310. Positron emission tomography in the evaluation of the negative neck in patients with oral cavity cancer
311. Contribution of PET in the detection of liver metastases from pancreatic tumours
312. Clinical contribution of FDG-PET for follow-up patients with gynecological malignancies
313. Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum
314. Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: Correlation with CT
315. PET Scanning with 18F2-fluoro-2-deoxy-D-glucose(FDG) in patients with melanoma: Benefits and limitations
316. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer
317. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma
318. Whole body positron emission tomography in breast cancer
319. Is FDG PET indicated when cancer disease of the pancreas is diagnosed based on CT?
320. Diagnostic value of positron emission tomography for detecting breast cancer
321. Detection of cancer in augmented breasts by positron emission tomography
322. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI
323. Does post radiation therapy change in the lung affect the accuracy of FDG-PET in the evaluation of tumor recurrence in lung cancer?
324. FDG-PET imaging of residual testicular cancer after chemotherapy
325. Detection of recurrent and metastatic colorectal cancer: Comparison of positron emission tomography and computed tomography
326. Efficacy of F-18 fluorodeoxyglucose positron emission tomography (FDG-PET) scans in diagnosis of pulmonary nodules
327. Clinical significance of L-(3-18F)-alpha-methyl tyrosine PET studies in intracranial and intrathoracic tumor: A comparative study with 18F-FDG PET
328. The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer
329. FDG-PET for evaluating the effectiveness of endocrine therapy for prostate cancer
330. FDG-PET in metastasized colorectal carcinoma
331. Fluorine-18 fluorodeoxyglucose imaging using dual-head coincidence positron emission tomography without attenuation correction in patients with head and neck cancer
332. Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumors
333. An appraisal of 18-fluorodeoxyglucose positron emission tomography for melanoma staging
334. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma
335. Focal pulmonary abnormalities: Evaluation with F-18 fluorodeoxyglucose PET scanning
336. Persistent or recurrent bronchogenic carcinoma: Detection with PET and 2-(F-18)-12-deoxy-D-glucose
337. 18FDG PET for the assessment of primary head and neck tumors: Clinical, computed tomography, and histopathological correlation in 38 patients
338. Positron emission tomography findings relevant to neurosurgery for epilepsy
339. FDG PET identify residual or recurrent disease following local ablation of liver metastases
340. Controlled prospective study of positron emission tomography using the glucose analogue [18F]fluorodeoxyglucose in the evaluation of pulmonary nodules
341. Staging of gastroesophageal cancer with PET using 11C choline and 18F FDG
342. Brain tumor recurrence versus radiation necrosis: Role of Tc-99m MIB1 compared to FDG PET
343. Preoperative staging of patients (PTS) with non-small cell lung cancer (NSCLC) using 18FDG imaging: Comparison of dual-head coincidence (DHC) gamma-camera versus dedicated PET
344. Computed tomography and positron emission tomography in the pre-operative staging of oesophageal carcinoma
345. Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers
346. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose
347. PET-FDG versus CT in the staging and detection of relapse in patients with Hodgkin's disease or non-Hodgkin lymphoma: Two years experience
348. Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients
349. Clinical role of positron emission tomography in children with tuberous sclerosis complex
350. Metabolic characterization of ovarian tumors with positron emission tomography and F-18 fluorodeoxyglucose
351. Positron emission tomography for evaluating para-aortic nodal metastasis in locally advanced cervical cancer before surgical staging: A surgicopathologic study
352. Positron emission tomography in breast cancer: A clinicopathological correlation of results
353. Acute changes in glucose uptake after treatment: The effects of carmustine (BCNU) on human glioblastoma multiforme
354. Fluorodeoxyglucose whole-body positron emission tomography in colorectal cancer patients studied in routine daily practice
355. FDG-PET in evaluating therapeutic effect and restaging of non-small cell lung cancer after neoadjuvant chemoradiotherapy: Correlation with histopathology
356. The role of positron emission tomography in occult primary head and neck cancers
357. Presurgical evaluation and surgical outcome of temporal lobe epilepsy
358. FDG-PET and MRI in temporal lobe epilepsy: Relationship to febrile seizures, hippocampal sclerosis and outcome
359. Differential diagnosis of Alzheimer's disease with PET
360. Positron emission tomography with 18-fluorine-labelled deoxyglucose: Utility in localized and advanced prostate cancer
361. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: A comparative study with X-ray computed tomography
362. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer
363. Comparison of [11C]flumazenil and [18F]FDG as PET markers of epileptic foci
364. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer
365. Qualitative [18F] FDG positron emission tomography in primary breast cancer: Clinical relevance and practicability
366. Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer
367. Characterization of solitary pulmonary nodules and lung cancer with FDG-PET
368. Contribution of PET in the diagnosis of recurrent colorectal cancer: Comparison with conventional imaging
369. Staging of recurrent lung cancer: Value of FDG-PET in therapy selection and management of patients
370. Staging of newly diagnosed lung cancer: Impact of FDG-PET on patient management
371. Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography
372. Planar bone imaging vs 18F-PET in patients with cancer of the prostate, thyroid and lung
373. FDG-PET in preoperative staging of breast cancer
374. FDG-PET in patients with suspected recurrence of colorectal cancer. Is there a contribution to surgical decision finding?
375. Histological verification of positive fluorine-18 fluorodeoxyglucose findings in patients with differentiated thyroid cancer
376. Blood flow-metabolism imaging with positron emission tomography in patients with diabetes mellitus for the assessment of reversible left ventricular contractile dysfunction
377. Comparison of hybrid PET system and dedicated PET-scanner in patients with colon cancer and indeterminate liver lesion
378. Fluorodeoxyglucose positron emission tomography of soft tissue turnouts: Is a non-invasive determination of biological activity possible?
379. Functional imaging and detection of local recurrence in soft tissue sarcomas by positron emission tomography
380. Clinical value of [18-F] fluorodeoxyglucose positron emission tomography imaging in soft tissue sarcomas
381. Mediastinal lymph node staging of non-small-cell lung cancer: A prospective comparison of computed tomography and positron emission tomography
382. Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F] fluorodeoxyglucose
383. Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer
384. Comparison of whole-body 11C acetate and FDG PET in patients with prostate cancer
385. Prospective survey of referring physicians to determine the impact of whole-body FDG-PET on management of cancer patients
386. The impact of FDG positron emission tomography imaging on the management of lymphomas
387. The clinical utility of 18FDG PET in the management of iodine-negative thyroid cancer
388. FDG-PET evaluation of pancreatic cancer treatment
389. Temporal lobectomy in adults with intractable epilepsy
390. Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18] fluoro-D-glucose
391. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: Dualhead coincidence gamma camera versus positron emission tomographic scanner
392. Neoplasms in a pediatric population: 2-(F-18)-fluoro-2-deoxy-D-glucose PET studies
393. Pheochromocytomas: Imaging with 2-(fluorine-18)fluoro-2-deoxy-D-glucose PET
394. Prognostic value of regional brain metabolism in evaluation of dementia: Comparison with long-term clinical outcome
395. Prognostic value of brain PET in patients with early dementia symptoms, treated or untreated with anticholinesterase therapy
396. Diagnostic accuracy of FDG-PET in evaluation of dementia: International multi-center pooled brain scan and autopsy data
397. Satellite PET and lung cancer: A prospective study in surgical patients
398. Avoiding second-look surgery and reducing costs in managing patients with ovarian cancer by applying F-18-FDG PET
399. Staging of the axilla in breast cancer: Accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose
400. 18F-FDG PET may predict the pathological response of breast cancer to primary chemotherapy
401. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy
402. Usefulness of [18F]fluorodeoxyglucose positron emission tomography in pediatric epilepsy surgery
403. Positron emission tomography with fluorodeoxyglucose after first line chemotherapy in non-Hodgkin's lymphoma
404. Functional and morphological abnormalities in temporal lobe epilepsy: A comparison of interictal and ictal EEG, CT, MRI, SPECT and PET
405. Non-small cell lung cancer: Nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling
406. Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose
407. Planar coincidence scintigraphy and PET in staging malignant melanoma
408. Effectiveness of whole-body FDG PET imaging in staging of non-small-cell lung cancer (NSCLC)
409. Differentiation between recurrent brain tumour and post-radiation necrosis: The value of 201TI SPET versus 18F-FDG PET using a dual-headed coincidence camera. A pilot study
410. Fluorine-18 fluorodeoxyglucose dual-head positron emission tomography in the detection of recurrent differentiated thyroid cancer: Preliminary results
411. The detection of local recurrent head and neck cancer with fluorine-18 fluorodeoxyglucose dual-head positron emission tomography
412. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: Value of quantitative image interpretation
413. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: Effectiveness and comparison with computed tomography
414. Evaluation of FDG PET in patients with cervical cancer
415. FDG-PET in evaluation of brachial plexopathy in patients with previously-treated breast cancer
416. Neuroimaging in patients with seizures of probable frontal lobe origin
417. Quantitative EEG mapping and PET in Alzheimer's disease
418. Clinical assessment of positron emission tomography for the diagnosis of local recurrence in colorectal cancer
419. Prediction of reversible ischemia after revascularization: Perfusion and metabolic studies with positron emission tomography
420. Positron emission tomography using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting
421. Presurgical identification of epileptic foci with iodine-123 iomazenil SPET: Comparison with brain perfusion SPET and FDG PET
422. Whole-body hybrid positron emission tomography with 18F-FDG in the staging of non-Hodgkin's lymphoma
423. Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: Comparison with FDG PET
424. Heterogeneous cerebral glucose metabolism in normal pressure hydrocephalus
425. Neuroimaging in refractory partial seizures: Comparison of PET, CT, and MR1
426. FDG-positron emission tomography and invasive EEG: Seizure focus detection and surgical outcome
427. Distinguishing recurrent tumor and radiation necrosis with positron emission tomography versus stereotactic biopsy
428. Reversibility of cardiac wall motion abnormalities predicted by positron tomography
429. 18F-FDG imaging of lymphoma in children using a hybrid PET system: Comparison with 67Ga
430. Role of whole-body FDG-PET in management of patients with recurrent ovarian cancers
431. Metabolic response of non-Hodgkin's lymphoma to 1311-anti-B1 radioimmunotherapy: Evaluation with FDG PET
432. The efficacy of FDG-PET in the management of non-small cell lung cancer
433. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma
434. Peritoneal carcinomatosis: The role of FDG-PET
435. Prospective evaluation of fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry
436. Whole-body PET imaging with F-18 fluorodeoxyglucose in management of recurrent colorectal cancer
437. Staging non-small cell lung cancer by whole-body positron emission tomographic imaging
438. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma
439. Medlastinal lymph node staging with FDG-PET scan in patients with potentially operable non-small cell lung cancer. A prospective analysis of 50 cases
440. FDG-PET scan in potentially operable non-small cell lung cancer: Do anatometabolic PET-CT fusion images improve the localisation of regional lymph node metastases?
441. Fluorodeoxyglucose and bronchopulmonary cancer. Initial French results with positron emission tomography
442. Positron emission tomography to stage suspected metastatic colorectal carcinoma to the liver
443. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy
444. Initial assessment of positron emission tomography for detection of nonpalpable regional lymphatic metastases in melanoma
445. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: Preliminary prospective evaluation
446. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: Initial evaluation
447. Tc-99m MIBI imaging in patients with lung cancer: Comparison with CT and fluorine-18 FDG PET studies
448. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)] whole body scans and elevated serum thyroglobulin levels
449. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors
450. Imaging of lung cancer: Comparison of C-11-methionine and F-18-FDG PET
451. Detection of extrathoracic metastases by positron emission tomography in lung cancer
452. Usefulness of FDG-PET scan in the assessment of suspected metastatic or recurrent adenocarcinoma of the colon and rectum
453. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease
454. Impact of FDG-PET on management of patients with melanoma
455. Supra-CT detection of N3 or M1 lesions of NSC lung cancer by 18F FDG PET
456. PET-FDG imaging in the clinical evaluation of head and neck cancer
457. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma
458. Whole body (18F) FDG PET in patients with cervical lymph node metastases of unknown primary site
459. FDG-PET influences the clinical management of lymphoma patients
460. Evaluation of FDG-PET for the clinical management of breast cancer patients
461. Colorectal cancer recurrence in the liver: Detection by PET
462. Twenty percent of bony metastases of hormone-resistant prostate cancer are detected by PET-FDG whole body scanning
463. FDG-PET in esophageal cancer: Incremental value over computed tomography
464. Correlation of F-18-FDG and Tc-99m-MIBI uptake with proliferative activity in breast cancer
465. Comparison of FDG-PET with MIBISPECT in the detection of breast cancer and axillary lymph node metastasis
466. Effect of patients' being prone during FDG PET for the diagnosis of breast cancer
467. Detectability of FDG-PET and MIBI-SPECT to breast tumor
468. Functional imaging of head and neck tumours using positron emission tomography
469. The crucial role of FDG-PET in the evaluation of liver metastasis from colorectal cancer
470. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: A report of 106 cases
471. Hybrid PET vs. conventional imaging in the diagnosis of head and neck tumors
472. 18F-fluorodeoxyglucose PET in ovarian carcinoma: Methodology and preliminary results
473. The role of positron emission tomography (PET) in the management of lymphoma patients